1
|
Nordhoff S. A conceptual framework for automation disengagements. Sci Rep 2024; 14:8654. [PMID: 38622166 PMCID: PMC11018869 DOI: 10.1038/s41598-024-57882-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2023] [Accepted: 03/22/2024] [Indexed: 04/17/2024] Open
Abstract
A better understanding of automation disengagements can lead to improved safety and efficiency of automated systems. This study investigates the factors contributing to automation disengagements initiated by human operators and the automation itself by analyzing semi-structured interviews with 103 users of Tesla's Autopilot and FSD Beta. The factors leading to automation disengagements are represented by categories. In total, we identified five main categories, and thirty-five subcategories. The main categories include human operator states (5), human operator's perception of the automation (17), human operator's perception of other humans (3), the automation's perception of the human operator (3), and the automation incapability in the environment (7). Human operators disengaged the automation when they anticipated failure, observed unnatural or unwanted automation behavior (e.g., erratic steering, running red lights), or believed the automation is not capable to operate safely in certain environments (e.g., inclement weather, non-standard roads). Negative experiences of human operators, such as frustration, unsafe feelings, and distrust represent some of the adverse human operate states leading to automation disengagements initiated by human operators. The automation, in turn, monitored human operators and disengaged itself if it detected insufficient vigilance or speed rule violations by human operators. Moreover, human operators can be influenced by the reactions of passengers and other road users, leading them to disengage the automation if they sensed discomfort, anger, or embarrassment due to the automation's actions. The results of the analysis are synthesized into a conceptual framework for automation disengagements, borrowing ideas from the human factor's literature and control theory. This research offers insights into the factors contributing to automation disengagements, and highlights not only the concerns of human operators but also the social aspects of this phenomenon. The findings provide information on potential edge cases of automated vehicle technology, which may help to enhance the safety and efficiency of such systems.
Collapse
Affiliation(s)
- S Nordhoff
- Department Transport and Planning, Delft University of Technology, Delft, The Netherlands.
| |
Collapse
|
2
|
Pletinckx K, Vaßen S, Schlusche I, Nordhoff S, Bahrenberg G, Dunkern TR. Inhibiting the immunoproteasome's β5i catalytic activity affects human peripheral blood-derived immune cell viability. Pharmacol Res Perspect 2019; 7:e00482. [PMID: 31236277 PMCID: PMC6581949 DOI: 10.1002/prp2.482] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2018] [Revised: 04/01/2018] [Accepted: 04/05/2019] [Indexed: 01/03/2023] Open
Abstract
Small molecule inhibitors selectively targeting the immunoproteasome subunit β5i are currently being developed for the treatment of autoimmune disorders. However, patients carrying loss-of-function mutations in the gene encoding β5i (Psmb8) suffer from the proteasome-associated autoinflammatory syndromes (PRAAS) emphasizing the need to study pharmacological inhibition of immunoproteasome function in human cells. Here, we characterized the immunomodulatory potential of the selective β5i inhibitor ONX 0914 and Bortezomib, a pan-proteasome inhibitor, in human peripheral blood mononuclear cells (PBMCs). Both compounds efficiently blocked pro-inflammatory cytokine secretion in human whole blood and PBMC cultures stimulated with toll-like receptor (TLR) agonists. Furthermore, the compounds inhibited T cell cytokine production induced by recall antigen CMVpp65 or by polyclonal stimulation. The viability of PBMCs, however, was rapidly decreased in the presence of ONX 0914 and Bortezomib demonstrated by decreased residual cytosolic ATP and increased Annexin V surface binding. Interestingly, HLA-DR + monocytes were rapidly depleted from the cultures in the presence of ONX 0914 as a β5i-selective inhibitor and Bortezomib. In conclusion, the anti-inflammatory potential of β5i-selective inhibitors is correlating with a cytotoxicity increase in human PBMC subsets ex vivo. Our results provide important insights into the anti-inflammatory mechanism of action of β5i-inhibitors which currently hold the promise as a novel therapy for autoinflammatory diseases.
Collapse
|
3
|
Alen J, Schade M, Wagener M, Christian F, Nordhoff S, Merla B, Dunkern TR, Bahrenberg G, Ratcliffe P. Fragment-Based Discovery of Novel Potent Sepiapterin Reductase Inhibitors. J Med Chem 2019; 62:6391-6397. [DOI: 10.1021/acs.jmedchem.9b00218] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Affiliation(s)
- Jo Alen
- Grünenthal GmbH, Zieglerstraße 6, 52078 Aachen, Germany
| | - Markus Schade
- Grünenthal GmbH, Zieglerstraße 6, 52078 Aachen, Germany
| | | | | | | | - Beatrix Merla
- Grünenthal GmbH, Zieglerstraße 6, 52078 Aachen, Germany
| | | | | | | |
Collapse
|
4
|
Dallmann R, Weyermann P, Anklin C, Boroff M, Bray-French K, Cardel B, Courdier-Fruh I, Deppe H, Dubach-Powell J, Erb M, Haefeli RH, Henneböhle M, Herzner H, Hufschmid M, Marks DL, Nordhoff S, Papp M, Rummey C, Santos G, Schärer F, Siendt H, Soeberdt M, Sumanovski LT, Terinek M, Mondadori C, Güven N, Feurer A. The orally active melanocortin-4 receptor antagonist BL-6020/979: a promising candidate for the treatment of cancer cachexia. J Cachexia Sarcopenia Muscle 2011; 2:163-174. [PMID: 21966642 PMCID: PMC3177041 DOI: 10.1007/s13539-011-0039-1] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/09/2011] [Accepted: 08/16/2011] [Indexed: 12/23/2022] Open
Abstract
BACKGROUND: Under physiological conditions, the melanocortin system is a crucial part of the complex network regulating food intake and energy expenditure. In pathological states, like cachexia, these two parameters are deregulated, i.e., food intake is decreased and energy expenditure is increased-a vicious combination leading to catabolism. Agouti-related protein (AgRP), the endogenous antagonist at the melanocortin-4 receptor (MC-4R), was found to increase food intake and to reduce energy expenditure. This qualifies MC-4R blockade as an attractive mode of action for the treatment of cachexia. Based on this rationale, a novel series of small-molecule MC-4R antagonists was designed, from which the orally active compound BL-6020/979 (formerly known as SNT207979) emerged as the first promising development candidate showing encouraging pre-clinical efficacy and safety properties which are presented here. METHODS AND RESULTS: BL-6020/979 is an orally available, selective and potent MC-4R antagonist with a drug-like profile. It increased food intake and decreased energy expenditure in healthy wild-type but not in MC-4R deficient mice. More importantly, it ameliorated cachexia-like symptoms in the murine C26 adenocarcinoma model; with an effect on body mass and body composition and on the expression of catabolic genes. Moreover, BL-6020/979 showed antidepressant-like properties in the chronic mild stress model in rats and exhibits a favorable safety profile. CONCLUSION: The properties of BL-6020/979 demonstrated in animal models and presented here make it a promising candidate suitable for further development towards a first-in-class treatment option for cachexia that potentially opens up the opportunity to treat two hallmarks of the disease, i.e., decreased food intake and increased energy expenditure, with one drug.
Collapse
Affiliation(s)
- R. Dallmann
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
- Institute of Pharmacology and Toxicology; University of Zurich; Winterthurerstr. 190 8057 Zurich
| | - P. Weyermann
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - C. Anklin
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - M. Boroff
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - K. Bray-French
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - B. Cardel
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - I. Courdier-Fruh
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - H. Deppe
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - J. Dubach-Powell
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - M. Erb
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - R. H. Haefeli
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - M. Henneböhle
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - H. Herzner
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - M. Hufschmid
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - D. L. Marks
- Department of Pediatric Endocrinology, Vollum Institute; Oregon Health Sciences University; Portland
| | - S. Nordhoff
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - M. Papp
- Institute of Pharmacology; Polish Academy of Sciences; Krakow
| | - C. Rummey
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - G. Santos
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - F. Schärer
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - H. Siendt
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - M. Soeberdt
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - L. T. Sumanovski
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - M. Terinek
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - C. Mondadori
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - N. Güven
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| | - A. Feurer
- Santhera Pharmaceuticals (Switzerland) Ltd.; Hammerstr. 49 4410 Liestal
| |
Collapse
|
5
|
Nordhoff S, Bulat S, Cerezo-Gálvez S, Hill O, Hoffmann-Enger B, López-Canet M, Rosenbaum C, Rummey C, Thiemann M, Matassa VG, Edwards PJ, Feurer A. The design of potent and selective inhibitors of DPP-4: optimization of ADME properties by amide replacements. Bioorg Med Chem Lett 2009; 19:6340-5. [PMID: 19833514 DOI: 10.1016/j.bmcl.2009.09.078] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2009] [Revised: 09/18/2009] [Accepted: 09/20/2009] [Indexed: 11/18/2022]
Abstract
For a series of beta-homophenylalanine based inhibitors of dipeptidyl peptidase IV ADME properties were improved by the incorporation of amide replacements. These efforts led to a novel series of potent and selective inhibitors of DPP-4 that exhibit an attractive pharmacokinetic profile and show excellent efficacy in an animal model of diabetes.
Collapse
Affiliation(s)
- Sonja Nordhoff
- Santhera Pharmaceuticals (Switzerland) Ltd, Hammerstrasse 47, CH-4410 Liestal, Switzerland.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Nordhoff S, López-Canet M, Hoffmann-Enger B, Bulat S, Cerezo-Gálvez S, Hill O, Rosenbaum C, Rummey C, Thiemann M, Matassa VG, Edwards PJ, Feurer A. From lead to preclinical candidate: Optimization of β-homophenylalanine based inhibitors of dipeptidyl peptidase IV. Bioorg Med Chem Lett 2009; 19:4818-23. [DOI: 10.1016/j.bmcl.2009.06.036] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2009] [Revised: 06/10/2009] [Accepted: 06/10/2009] [Indexed: 10/20/2022]
|
7
|
Nordhoff S, Cerezo-Gálvez S, Deppe H, Hill O, López-Canet M, Rummey C, Thiemann M, Matassa VG, Edwards PJ, Feurer A. Discovery of beta-homophenylalanine based pyrrolidin-2-ylmethyl amides and sulfonamides as highly potent and selective inhibitors of dipeptidyl peptidase IV. Bioorg Med Chem Lett 2009; 19:4201-3. [PMID: 19515557 DOI: 10.1016/j.bmcl.2009.05.109] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2009] [Revised: 05/25/2009] [Accepted: 05/27/2009] [Indexed: 11/19/2022]
Abstract
Modifications of DPP-4 inhibitor 5, that was discovered by structure based design, are described and structure-activity relationships discussed. With analogue 7k one of the most potent non-covalent inhibitors of DPP-4 reported to date (IC(50)=0.38nM) was discovered. X-ray structure of inhibitor 7k bound to DPP-4 revealed a hydrogen bonding interaction with Q553. First successful efforts in balancing overall properties, as demonstrated by improved metabolic stability, highlight the potential of this series.
Collapse
Affiliation(s)
- Sonja Nordhoff
- Santhera Pharmaceuticals (Switzerland) Ltd, Hammerstrasse 47, CH-4410 Liestal, Switzerland.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
8
|
Dallmann R, Weyermann P, Magyar JP, Anklin C, Hufschmid M, Nordhoff S, Henneböhle M, Dubach- Powell J, Courdier-Fruh I, Mondadori C. Efficacy of orally available selective melanocortin-4 receptor antagonists in a murine model of cancer cachexia. J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.e20668] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
e20668 Background: Cachexia is among the most debilitating and life-threatening aspects of cancer. It represents a metabolic syndrome affecting essential functional circuits involved in the regulation of homeostasis, and includes anorexia, fat and muscle tissue wasting. The anorexigenic peptide alpha-MSH is believed to be crucially involved in the normal and pathologic regulation of food intake. It was speculated that blockade of its central physiological target, the melanocortin (MC)-4 receptor, might provide a promising anti-cachexia treatment strategy. This idea is supported by the fact that in animal studies, agouti-related protein (AgRP), the endogenous inverse agonist at the MC-4 receptor, was found to affect two hallmark features of cachexia, i.e. to increase food intake and to reduce energy expenditure. Methods: Two recently discovered, non peptidic, chemically unrelated, orally active MC-4 receptor antagonists penetrating the blood brain barrier were studied. Specifically, the influence on food intake in healthy mice, and effects in the murine C26 cancer-cachexia model were investigated. Results: Both compounds were found to distinctly increase food intake in healthy mice. Moreover, in mice subcutaneously implanted with C26 adenocarcinoma cells, repeated oral administration (starting the day after tumor implantation) of each of the two compounds almost completely prevented tumor induced weight loss, and diminished loss of lean body mass and fat mass. Conclusions: In contrast to the previously reported peptidic and small molecule MC-4 antagonists, the compounds described here work by the oral administration route. In the light of patient care, orally active compounds might offer a considerable advantage for the treatment of cancer cachexia. [Table: see text]
Collapse
Affiliation(s)
- R. Dallmann
- Santhera Pharmaceuticals (Switzerland) Ltd., Liestal, Switzerland
| | - P. Weyermann
- Santhera Pharmaceuticals (Switzerland) Ltd., Liestal, Switzerland
| | - J. P. Magyar
- Santhera Pharmaceuticals (Switzerland) Ltd., Liestal, Switzerland
| | - C. Anklin
- Santhera Pharmaceuticals (Switzerland) Ltd., Liestal, Switzerland
| | - M. Hufschmid
- Santhera Pharmaceuticals (Switzerland) Ltd., Liestal, Switzerland
| | - S. Nordhoff
- Santhera Pharmaceuticals (Switzerland) Ltd., Liestal, Switzerland
| | - M. Henneböhle
- Santhera Pharmaceuticals (Switzerland) Ltd., Liestal, Switzerland
| | | | - I. Courdier-Fruh
- Santhera Pharmaceuticals (Switzerland) Ltd., Liestal, Switzerland
| | - C. Mondadori
- Santhera Pharmaceuticals (Switzerland) Ltd., Liestal, Switzerland
| |
Collapse
|
9
|
Weyermann P, Dallmann R, Magyar J, Anklin C, Hufschmid M, Dubach-Powell J, Courdier-Fruh I, Henneböhle M, Nordhoff S, Mondadori C. Orally available selective melanocortin-4 receptor antagonists stimulate food intake and reduce cancer-induced cachexia in mice. PLoS One 2009; 4:e4774. [PMID: 19295909 PMCID: PMC2654097 DOI: 10.1371/journal.pone.0004774] [Citation(s) in RCA: 46] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2008] [Accepted: 01/23/2009] [Indexed: 12/23/2022] Open
Abstract
Background Cachexia is among the most debilitating and life-threatening aspects of cancer. It represents a metabolic syndrome affecting essential functional circuits involved in the regulation of homeostasis, and includes anorexia, fat and muscle tissue wasting. The anorexigenic peptide α-MSH is believed to be crucially involved in the normal and pathologic regulation of food intake. It was speculated that blockade of its central physiological target, the melanocortin (MC)-4 receptor, might provide a promising anti-cachexia treatment strategy. This idea is supported by the fact that in animal studies, agouti-related protein (AgRP), the endogenous inverse agonist at the MC-4 receptor, was found to affect two hallmark features of cachexia, i.e. to increase food intake and to reduce energy expenditure. Methodology/Principal Findings SNT207707 and SNT209858 are two recently discovered, non peptidic, chemically unrelated, orally active MC-4 receptor antagonists penetrating the blood brain barrier. Both compounds were found to distinctly increase food intake in healthy mice. Moreover, in mice subcutaneously implanted with C26 adenocarcinoma cells, repeated oral administration (starting the day after tumor implantation) of each of the two compounds almost completely prevented tumor induced weight loss, and diminished loss of lean body mass and fat mass. Conclusions/Significance In contrast to the previously reported peptidic and small molecule MC-4 antagonists, the compounds described here work by the oral administration route. Orally active compounds might offer a considerable advantage for the treatment of cachexia patients.
Collapse
Affiliation(s)
- Philipp Weyermann
- Santhera Pharmaceuticals (Switzerland) Ltd., Liestal, Switzerland
- * E-mail:
| | - Robert Dallmann
- Santhera Pharmaceuticals (Switzerland) Ltd., Liestal, Switzerland
| | - Josef Magyar
- Santhera Pharmaceuticals (Switzerland) Ltd., Liestal, Switzerland
| | - Corinne Anklin
- Santhera Pharmaceuticals (Switzerland) Ltd., Liestal, Switzerland
| | | | | | | | - Marco Henneböhle
- Santhera Pharmaceuticals (Switzerland) Ltd., Liestal, Switzerland
| | - Sonja Nordhoff
- Santhera Pharmaceuticals (Switzerland) Ltd., Liestal, Switzerland
| | - Cesare Mondadori
- Santhera Pharmaceuticals (Switzerland) Ltd., Liestal, Switzerland
| |
Collapse
|
10
|
|
11
|
Nordhoff S. Die Bedeutung nachwachsender Rohstoffe in der chemischen Industrie. CHEM-ING-TECH 2006. [DOI: 10.1002/cite.200650346] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
12
|
Busch R, Hirth T, Liese A, Nordhoff S, Puls J, Pulz O, Sell D, Syldatk C, Ulber R. Nutzung nachwachsender Rohstoffe in der industriellen Stoffproduktion. CHEM-ING-TECH 2006. [DOI: 10.1002/cite.200500178] [Citation(s) in RCA: 17] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
|
13
|
Nordhoff S, Cerezo-Gálvez S, Feurer A, Hill O, Matassa VG, Metz G, Rummey C, Thiemann M, Edwards PJ. The reversed binding of β-phenethylamine inhibitors of DPP-IV: X-ray structures and properties of novel fragment and elaborated inhibitors. Bioorg Med Chem Lett 2006; 16:1744-8. [PMID: 16376544 DOI: 10.1016/j.bmcl.2005.11.103] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2005] [Revised: 11/29/2005] [Accepted: 11/30/2005] [Indexed: 11/30/2022]
Abstract
The co-crystal structure of beta-phenethylamine fragment inhibitor 5 bound to DPP-IV revealed that the phenyl ring occupied the proline pocket of the enzyme. This finding provided the basis for a general hypothesis of a reverse binding mode for beta-phenethylamine-based DPP-IV inhibitors. Novel inhibitor design concepts that obviate substrate-like structure-activity relationships (SAR) were thereby enabled, and novel, potent inhibitors were discovered.
Collapse
Affiliation(s)
- Sonja Nordhoff
- Medicinal Chemistry, Santhera Pharmaceuticals, Im Neuenheimer Feld 518-519, D-69120 Heidelberg, Germany.
| | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Rummey C, Nordhoff S, Thiemann M, Metz G. In silico fragment-based discovery of DPP-IV S1 pocket binders. Bioorg Med Chem Lett 2006; 16:1405-9. [PMID: 16321524 DOI: 10.1016/j.bmcl.2005.11.038] [Citation(s) in RCA: 39] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2005] [Revised: 11/10/2005] [Accepted: 11/10/2005] [Indexed: 11/27/2022]
Abstract
Dipeptidyl peptidase IV is a clinically validated target for type-2 diabetes and belongs to a family of peptidases with a quite unique post-proline cleavage specificity. Known inhibitors contain a limited number of molecular anchors occupying the small prototypical S1 pocket. A virtual screening approach for such S1-binding fragments was carried out using FlexX docking to evaluate its potential to confirm known and find novel compounds. Several low molecular weight inhibitors exhibiting activities in the micromolar range could be identified as starting points for structure-based design.
Collapse
Affiliation(s)
- Christian Rummey
- Computational Discovery, Santhera Pharmaceuticals, Im Neuenheimer Feld 518-519, 69120 Heidelberg, Germany
| | | | | | | |
Collapse
|
15
|
Mahmud T, Bode HB, Silakowski B, Kroppenstedt RM, Xu M, Nordhoff S, Höfle G, Müller R. A novel biosynthetic pathway providing precursors for fatty acid biosynthesis and secondary metabolite formation in myxobacteria. J Biol Chem 2002; 277:32768-74. [PMID: 12084727 DOI: 10.1074/jbc.m205222200] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Short chain carboxylic acids are well known as the precursors of fatty acid and polyketide biosynthesis. Iso-fatty acids, which are important for the control of membrane fluidity, are formed from branched chain starter units (isovaleryl-CoA and isobutyryl-CoA), which in turn are derived from the degradation of leucine and valine, respectively. Branched chain carboxylic acids are also employed as starter molecules for the biosynthesis of secondary metabolites, e.g. the therapeutically important anthelmintic agent avermectin or the electron transport inhibitor myxothiazol. During our studies on myxothiazol biosynthesis in the myxobacterium, Stigmatella aurantiaca, we detected a novel biosynthetic route to isovaleric acid. After cloning and inactivation of the branched chain keto acid dehydrogenase complex, which is responsible for the degradation of branched chain amino acids, the strain is still able to produce iso-fatty acids and myxothiazol. Incorporation studies employing deuterated leucine show that it can only serve as precursor in the wild type strain but not in the esg mutant. Feeding experiments using (13)C-labeled precursors show that isovalerate is efficiently made from acetate, giving rise to a labeling pattern in myxothiazol that provides evidence for a novel branch of the mevalonate pathway involving the intermediate 3,3-dimethylacryloyl-CoA. 3,3-Dimethylacrylic acid was synthesized in deuterated form and fed to the esg mutant, resulting in strong incorporation into myxothiazol and iso-fatty acids. Similar experiments employing Myxococcus xanthus revealed that the discovered biosynthetic route described is present in other myxobacteria as well.
Collapse
Affiliation(s)
- Taifo Mahmud
- Gesellschaft für Biotechnologische Forschung, Mascheroder Weg 1, 38124 Braunschweig, Germany
| | | | | | | | | | | | | | | |
Collapse
|
16
|
|
17
|
Kobus A, Kuppinger FF, Meier R, Düssel R, Tuchlenski A, Nordhoff S. Improvement of Conventional Unit Operations by Hybrid Separation Technologies — A Review of Industrial Applications. CHEM-ING-TECH 2001. [DOI: 10.1002/1522-2640(200106)73:6<714::aid-cite7142222>3.0.co;2-s] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|